Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 financial results on April 30, 2026, highlighting a 196% year-over-year increase in Nociscan scan volumes and a 64% sequential increase from Q4 2025. The company attributed the growth to new account activations and deeper utilization within existing sites, signaling increasing integration of the Nociscan platform into clinical workflows for chronic low back pain management.
The company, a commercial-stage healthcare technology firm, uses biomarkers and proprietary augmented intelligence algorithms through its Nociscan platform to help physicians identify the source of chronic low back pain. According to the press release, approximately 5.8 million lumbar MRIs are performed annually in the U.S. for low back pain, representing a potential $2 billion market opportunity for technologies like Nociscan that provide objective evaluation of discogenic pain.
Brent Ness, CEO of Aclarion, stated, "Q1 represents a clear inflection for Aclarion. Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market."
Reimbursement progress is a key catalyst. Nociscan has been reimbursed by Vitality, AXA, and Aviva—three of the four largest private insurers in the U.K.—for several months, providing validation and a pathway for broader coverage. The company also launched a targeted direct-to-patient campaign in the U.K., including a video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, available here.
On the clinical front, Aclarion is advancing the CLARITY randomized trial to validate Nociscan's clinical utility in guiding treatment decisions. A preliminary internal readout is expected in the second half of 2026, with public disclosure of early interim results anticipated in late 2026. The company has seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials to support reimbursement discussions and potential local coverage decisions by commercial insurers.
Aclarion strengthened its intellectual property portfolio with a newly issued patent covering AI use in workflows of future products. The company now holds 64 issued and pending patents worldwide, enhancing its competitive position.
Financially, Aclarion reported $19.0 million in cash as of March 31, 2026, with no debt and a clean capital structure. The company also announced a $2.5 million share repurchase program. Based on current operating plans, management believes existing cash resources are sufficient to fund operations into the second half of 2027.
The company's strong balance sheet and accelerating adoption metrics suggest a promising trajectory. As adoption expands, Aclarion believes Nociscan can address a multi-billion-dollar market opportunity, potentially transforming the standard of care for discogenic pain evaluation.
